Contents

Highlights of This Issue 5543

SPECIAL FEATURES

Editorial

5545

Announcing the AACR Cancer Progress Report 2013

Jesse Potash and Kenneth C. Anderson

CCR Translations

5546

Better Performance of CARs Deprived of the PD-1 Brake

Aizea Morales-Kastesana, Sara Labiano, José I. Quetglas, and Ignacio Melero

See related article, p. 5549

5549

Coamplification and Cooperation: Toward Identifying Biologically Relevant Oncogenes

Guochang Huang and Bhuvanesh Singh

See related article, p. 5580

CCR Drug Updates

5552

Pertuzumab: Optimizing HER2 Blockade

Otto Metzger-Filho, Eric P. Winer, and Ian Krop

Molecular Pathways

5557

Molecular Pathways: Inflammation-Associated Nitric-Oxide Production as a Cancer-Supporting Redox Mechanism and a Potential Therapeutic Target

Elizabeth A. Grimm, Andrew G. Sikora, and Suhendan Ekmekcioglu

5564

Molecular Pathways: Human Leukocyte Antigen G (HLA-G)

Giuseppe Curigliano, Carmen Criscitiello, Lucia Gelao, and Aron Goldhirsch

Review

5572

The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer

Wen Wee Ma and Manuel Hidalgo

HUMAN CANCER BIOLOGY

5580

Integrative Genomics Analysis Identifies Candidate Drivers at 3q26-29 Amplicon in Squamous Cell Carcinoma of the Lung

Jing Wang, Jun Qian, Megan D. Hoeksema, Yong Zou, Allan V. Espinosa, S.M. Jamshedur Rahman, Bing Zhang, and Pierre P. Massion

See related article, p. 5549

5591

Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance


5602

miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression

Haolin Tang, Min Deng, Yunyun Tang, Xinhua Xie, Jiaoli Guo, Yanan Kong, Feng Ye, Qi Su, and Xiaoming Xie

5613

Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth

Muralimohan Yepuru, Zhongzhi Wu, Anand Kulkarni, Feng Yin, Christina M. Barrett, Juhyun Kim, Mitchell S. Steiner, Duane D. Miller, James T. Dalton, and Ramesh Narayan

CANCER THERAPY: PRECLINICAL

5626

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

Bertrand Allard, Sandra Pommey, Mark J. Smyth, and John Stagg

5636

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

Liza B. John, Christel Devaud, Connie P.M. Duong, Carmen S. Yong, Paul A. Beavis, Nicole M. Haynes, Melvyn T. Chow, Mark J. Smyth, Michael H. Kershaw, and Philip K. Darcy

See related article, p. 5546

The Journal of Clinical and Translational Research iii www.aacrjournals.org
Identification of Lethal microRNAs Specific for Head and Neck Cancer
Marlon Lindenbergh-van der Plas, Sanne R. Martens-de Kemp, Michiel de Maaker, Wessel N. van Wieringen, Bauke Ylstra, Reuven Agami, Francesco Cerisoli, C. René Leemans, Boudewijn J.M. Braakhuis, and Ruud H. Brakenhoff

Pharmacologic Inhibition of Jak2–Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer
Lei Gu, Zhiyong Liao, David T. Hoang, Ayush Dagvadorj, Shilpa Gupta, Shauna Blackmon, Elyse Ellsworth, Pooja Talati, Benjamin Leiby, Michael Zinda, Costas D. Lallas, Edouard J. Trabulsi, Peter McCue, Leonard Gomella, Dennis Huszar, and Marja T. Nevalainen

CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
Melinda Burgess, Devinder Gill, Richa Singhania, Catherine Cheung, Lynne Chambers, Brent A. Benyolds, Louise Smith, Peter Mollee, Nicholas Saunders, and Nigel AJ McMillan

RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
Xuefeng Yin, Leopoldo Luistro, Hua Zhong, Melissa Smith, Tom Nevins, Kathleen Schostack, Holly Hilton, Tai-An Lin, Theresa Truitt, Denise Biondi, Xiaoqian Wang, Kathryn Packman, Jim Rosinski, Wendy Berkofsky-Fessler, Juan-Ping Tang, Saimma Pant, David Geho, Suzana Vega-Harring, Mark DeMario, Hy Levitsky, and Mary Simcox

Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
Wenjuan Wu, Chen Bi, Kelly M. Credille, Jason R. Manro, Victoria L. Peek, Gregory P. Donoho, Lei Yan, John A. Wijsman, S. Betty Yan, and Richard A. Walgren

Preclinical Efficacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence, PET, and MRI
Erik S. Mittra, Hua Fan-Minogue, Frank I. Lin, Jason Karamchandani, Venkataraman Sriram, May Han, and Sanjiv S. Gambhir

The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

REM (Risk of Endometrial Malignancy): A Proposal for a New Scoring System to Evaluate Risk of Endometrial Malignancy
Roberto Angioli, Stella Capriglione, Alessia Aloisi, Daniela Lavero, Ester Valentina Cala, Nella Dugo, Roberto Monteria, Carlo De Cicco Nardone, Corrado Terranova, and Francesco Potti

The G-Protein–Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor Prognosis
Leonid L. Nikitenko, Russell Lerk, Stephen Henderson, Nischalan Pillay, Helen Turley, Daniele Generali, Sarah Gunningham, Helen R. Morrin, Andrea Pellagatti, Margaret C.P. Rees, Adrian L. Harris, and Stephen B. Fox

Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAF*V600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
Emanuela Romano, Sylvain Pradervand, Alexandra Paillasson, Johann Weber, Keith Harshman, Katja Muehlethaler, Daniel Speiser, Solange Peters, Donata Rimoldi, and Olivier Michielin
Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia

Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity
Sarah McWhinney-Glass, Stacey J. Winham, Daniel L. Hertz, Jane Yen Revollo, Jim Paul, Yijing He, Robert Brown, Alison A. Motsinger-Reif, and Howard L. McLeod; For the Scottish Gynaecological Clinical Trials Group

Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803

Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

The cover shows a section from the prostate of a patient with Gleason sum 7 prostate cancer. Duolink proximity ligation assay in the section shows strong interaction between AR and AKR1C3 (red). Nucleus was counterstained with DAPI and imaged using a fluorescent microscope. For details, see the article by Yepuru and colleagues on page 5613 of this issue.